跳至主要内容
临床试验/ACTRN12618000386235
ACTRN12618000386235尚未招募未知

Establishing an Australian reference range for striatal binding in patients with Parkinson’s disease and healthy controls with 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine (F-DOPA) PET.

Sir Charles Gairdner Hospital0 个研究点目标入组 30 人开始时间: 2018年3月15日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • Parkinson's disease: based on the UK Brain bank clinical criteria and a Hoehn and
  • Yahr score of 2.5 or less (early PD) or 3.0 or more (late PD).
  • Normal controls: aged matched individuals with no historical or clinical evidence of
  • any neurological disorder.
  • Greater than 18 years of age
  • Able to undertake PET imaging
  • Able to provide written informed consent

排除标准

  • Less than 18 years of age
  • Medical contraindication to PET or MRI imaging
  • Patients with concurrent psychiatric disorders, signs of severe cognitive deterioration and severe cardiovascular comorbidity.
  • Cognitive impairment considered to impair the ability to give written informed consent in the opinion of the treating clinician

研究者

相似试验